Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”

Neurology

Volumn 58, Issue 9, 2002, Pages 1441-1442

  Filippi, M ^a   Rovaris, M ^a   Rocca, M A ^a   Sormani, M P ^a   Comi, G ^a   Wolinsky, J S ^a  

^a San Raffaele ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85026169026     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes.” Neurology 2001; 57: 731-733.
2. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297.
3. van Walderveen MA, Lycklama A, Nijeholt GJ, et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 2001; 58: 76-81.